RxDoctor Payments Data

Eric Strauss, MD

Sports Medicine · New York, NYNPI 1508061748

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (45.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Vericel Corporation at 42.7% of the total. Reporting peaked in 2019 at $74,865 and has fallen 82.7% since, to $12,941 in 2025. Among sports medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$240,772in general payments, 2019–2025

Across 225 payments — averaging $1070.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vericel Corporation$103K
  • Smith+Nephew$100K
  • Globus Medical$10K
  • Arthrex$10K
  • Arcuro Medical Inc$8K
  • Gotham Surgical Solutions & Devices, Inc.$3K
  • plus $8K from 13 others
$59,175in research payments, 2019–2025

Across 21 payments — averaging $2817.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Fidia Pharma USA Inc.$28K
  • Vericel Corporation$17K
  • Bioventus LLC$5K
  • Cartiheal (2009) LTD.$5K
  • Smith+Nephew$5K
$27,388in ownership & investment interests, 2019–2025

Across 1 payment — averaging $27,388 each. An ownership or investment interest held by the physician or an immediate family member.

  • Overture Orthopaedics$27K

What the payments were for

  • Consulting fees$92,13738%
  • Speaking & faculty fees$109,60046%
  • Travel & lodging$29,95412%
  • Food & beverage$6,1083%
  • Education$2,9551%
  • Entertainment$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$240,772 in reported general payments places this provider in the 95th percentile of 403 sports medicine providers in New York.

See all sports medicine providers in New York

Medicare billing

Part B allowed, 2024
$51,222
Medicare patients
128
Services billed
412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Meloxicam75$138

Paid to pharmacies, not to this prescriber.

Other sports medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →